AU2022299103B2 - Methods of using aldosterone synthase inhibitors - Google Patents

Methods of using aldosterone synthase inhibitors

Info

Publication number
AU2022299103B2
AU2022299103B2 AU2022299103A AU2022299103A AU2022299103B2 AU 2022299103 B2 AU2022299103 B2 AU 2022299103B2 AU 2022299103 A AU2022299103 A AU 2022299103A AU 2022299103 A AU2022299103 A AU 2022299103A AU 2022299103 B2 AU2022299103 B2 AU 2022299103B2
Authority
AU
Australia
Prior art keywords
compound
day
dose
treatment
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022299103A
Other languages
English (en)
Other versions
AU2022299103A1 (en
Inventor
Mary BOND
Brian Murphy
Catherine Pearce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincor Pharma Inc
Original Assignee
Cincor Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincor Pharma Inc filed Critical Cincor Pharma Inc
Publication of AU2022299103A1 publication Critical patent/AU2022299103A1/en
Application granted granted Critical
Publication of AU2022299103B2 publication Critical patent/AU2022299103B2/en
Priority to AU2026201954A priority Critical patent/AU2026201954A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022299103A 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors Active AU2022299103B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201954A AU2026201954A1 (en) 2021-06-24 2026-03-16 Methods of using aldosterone synthase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163214521P 2021-06-24 2021-06-24
US63/214,521 2021-06-24
US202163290364P 2021-12-16 2021-12-16
US63/290,364 2021-12-16
PCT/US2022/073148 WO2022272300A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201954A Division AU2026201954A1 (en) 2021-06-24 2026-03-16 Methods of using aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
AU2022299103A1 AU2022299103A1 (en) 2024-01-25
AU2022299103B2 true AU2022299103B2 (en) 2025-12-18

Family

ID=84545863

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022299103A Active AU2022299103B2 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors
AU2026201954A Pending AU2026201954A1 (en) 2021-06-24 2026-03-16 Methods of using aldosterone synthase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201954A Pending AU2026201954A1 (en) 2021-06-24 2026-03-16 Methods of using aldosterone synthase inhibitors

Country Status (10)

Country Link
US (1) US20240277698A1 (https=)
EP (1) EP4358959A4 (https=)
JP (1) JP2024523559A (https=)
KR (1) KR20240035483A (https=)
AU (2) AU2022299103B2 (https=)
BR (1) BR112023027025A2 (https=)
CA (1) CA3223211A1 (https=)
IL (1) IL309428A (https=)
MX (1) MX2023015121A (https=)
WO (1) WO2022272300A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024310688A1 (en) * 2023-06-29 2026-01-29 AstraZeneca Ireland Limited Crystal form of baxdrostat, and preparation method therefor and use thereof
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
TW202525278A (zh) * 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
US20130079365A1 (en) * 2011-09-23 2013-03-28 Johannes Aebi New bicyclic dihydroquinoline-2-one derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
US20130079365A1 (en) * 2011-09-23 2013-03-28 Johannes Aebi New bicyclic dihydroquinoline-2-one derivatives

Also Published As

Publication number Publication date
EP4358959A1 (en) 2024-05-01
WO2022272300A1 (en) 2022-12-29
AU2022299103A1 (en) 2024-01-25
KR20240035483A (ko) 2024-03-15
IL309428A (en) 2024-02-01
US20240277698A1 (en) 2024-08-22
AU2026201954A1 (en) 2026-04-02
JP2024523559A (ja) 2024-06-28
EP4358959A4 (en) 2025-05-14
CA3223211A1 (en) 2022-12-29
MX2023015121A (es) 2024-04-16
BR112023027025A2 (pt) 2024-03-12

Similar Documents

Publication Publication Date Title
AU2022299103B2 (en) Methods of using aldosterone synthase inhibitors
JP2010518169A (ja) 心血管疾患の処置のためのラノラジンの使用
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
EP4058012A1 (en) Novel dosage forms of rofecoxib and related methods
US20260041679A1 (en) Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat
JP2025111453A (ja) 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
JP2011511844A (ja) 心血管疾患の処置のためのラノラジンの使用
AU2021388141A9 (en) Treatment of raynaud's disease
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
CN117545482A (zh) 使用醛固酮合酶抑制剂的方法
US20070053975A1 (en) Ramipril formulation
CN115666564B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
EP4673123A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
EP4525857A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
CA3256514A1 (en) PHLOROGLUCINOL FORMULATIONS AND METHODS OF USE
HK40082224B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
HK1147687A (en) Pharmaceutical formulation of valsartan

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)